| Objective:The clinical data of donor lymphocyte infusion(DLI)after allogeneic hematopoietic stem cell transplantation(allo-HSCT)were retrospectively analyzed to investigate the efficacy and safety of DLI in preventing relapse after allo-HSCT of hematological malignancy.Methods:From July 2012 to July 2017,a total of 90 patients with hematologic malignancies performed allo-HSCT in the Department of Hematology,Second Hospital of Hebei Medical University,including 28 patients with DLI in the DLI group.From the remaining 62 patients without DLI,40 patients matched the disease condition with DLI group were selected as nDLI group.The overall survival(OS)and acute graft-versus-host disease(aGVHD)were compared between the two groups.The effects of therapeutic DLI(t-DLI)on patients with hematological relapse after transplantation and prevention/preemptive DLI(pDLI)on patients with high-risk factors before transplantation or MRD-positive after transplantation were analyzed.Result: 1 Hematopoietic reconstitution was achieved in all 68 patients.2 Patients in the DLI group had higher OS at 1 year and 2 years than those in the nDLI group(92.2% vs 65.1% for 1 year OS and 77.8% vs 45.6% for 2 years OS,P<0.05).2.1 Nineteen patients with hematologic relapse after transplantation,and patients with tDLI(11 cases)had higher 1-year OS than patients with ntDLI(8 cases)(63.6% vs 14.3% for 1 year OS,P<0.05).2.2 Forty-nine patients with high-risk factors before transplantation or MRD-positive after transplantation,and patients with pDLI(17 cases)had higher OS at 1 year and 2 years than patients with npDLI(32 cases)(94.1% vs 86.9% for 1 year OS,79.3% vs 51.5% for 2 years OS,P<0.05).3 The incidence of aGVHD was higher in the DLI group than in the nDLI group(60.7% vs 35.0%).Conclusion: 1 DLI is an effective method to prevent relapse after allo-HSCT,more effective for high-risk transplant patients.2 DLI maybe increase the occurrence of aGVHD. |
PDF Full Text Request